<?xml version="1.0" encoding="UTF-8"?>
<ref id="bjh15394-bib-0017">
 <mixed-citation publication-type="journal" id="bjh15394-cit-0017">
  <string-name>
   <surname>Gupta</surname>, 
   <given-names>N.</given-names>
  </string-name>, 
  <string-name>
   <surname>Huh</surname>, 
   <given-names>Y.</given-names>
  </string-name>, 
  <string-name>
   <surname>Hutmacher</surname>, 
   <given-names>M.M.</given-names>
  </string-name>, 
  <string-name>
   <surname>Ottinger</surname>, 
   <given-names>S.</given-names>
  </string-name>, 
  <string-name>
   <surname>Hui</surname>, 
   <given-names>A.M.</given-names>
  </string-name> &amp; 
  <string-name>
   <surname>Venkatakrishnan</surname>, 
   <given-names>K.</given-names>
  </string-name> (
  <year>2015b</year>) 
  <article-title>Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients</article-title>. 
  <source xml:lang="en">Cancer Chemotherapy and Pharmacology</source>, 
  <volume>76</volume>, 
  <fpage>507</fpage>â€“
  <lpage>516</lpage>.
  <pub-id pub-id-type="pmid">26141494</pub-id>
 </mixed-citation>
</ref>
